Preliminary single-dose clinical pharmacokinetics of an anti–PD-L1 Probody therapeutic (Pb-Tx) in cancer patients.

Mark Stroh,Laura Serwer,Hong Lu,Vanessa Huels,Chihunt Wong,Beiyao Zheng,Bjorn L. Millard,Joshua F. Apgar,Nancy Zheng,Jennifer Richardson,Matthias Will,Rachel W. Humphrey

Preliminary single-dose clinical pharmacokinetics of an anti–PD-L1 Probody therapeutic (Pb-Tx) in cancer patients.

2018

Mark Stroh
Laura Serwer
Hong Lu
Vanessa Huels
Chihunt Wong
Beiyao Zheng
Bjorn L. Millard
Joshua F. Apgar
Nancy Zheng
Jennifer Richardson
Matthias Will
Rachel W. Humphrey

e14558Background: CX-072 is a protease-activatable antibody prodrug directed against programmed cell death ligand 1 (PD-L1). Probody therapeutics (Pb-Txs) are designed to be preferentially activate...

Keywords:

PD-L1
Cancer
Cancer research
Pathology
Medicine
Pharmacokinetics
Antibody
Programmed cell death ligand 1
Prodrug
Pharmacology
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations